TABLE 1.
Patient and procedural characteristics
|
Total N = 100 |
|
|---|---|
| Age, (median [IQR], years) | 67 (59, 74) |
| Height (mean [SD], cm) | 165.1 (8.9) |
| Weight (median [IQR], kg) | 65.7 (58.7, 73.6) |
| Sex (n [%], male) | 76 (76) |
| AF type (n [%]) | |
| Paroxysmal AF | 32 (32) |
| Persistent AF | 68 (68) |
| Medication (n [%]) | |
| AAD | 50 (50) |
| Anticoagulation | 100 (100) |
| Beta‐blocker | 49 (49) |
| Prior CV events (n [%]) | |
| TIA | 3 (3) |
| MI | 4 (4) |
| Stroke | 9 (9) |
| Comorbidities (n [%]) | |
| Hypertension | 59 (59) |
| Diabetes mellitus | 22 (22) |
| Heart failure | 16 (16) |
| Chronic kidney disease | 11 (11) |
| Valvular disease | 9 (9) |
| Thyroid disease | 9 (9) |
| Cardiomyopathy | 4 (4) |
| Congenital heart disease | 1 (1) |
| CHA2DS2‐VASc score (median, IQR) | 2 (1, 3) |
| CHA2DS2‐VASc score (n [%]) | |
| 0 | 12 (12) |
| 1 | 24 (24) |
| ≥2 | 64 (64) |
| Left atrial volume (mean [SD], mL) | 56.5 (18.0) |
| Left atrial diameter (mean [SD], mm) | 41.3 (5.6) |
| LVEF (median [IQR], %) | 63 (54, 68) |
| Ablation targets in addition to PVI (n [%]) | |
| CTI | 31 (31.0) |
| Linear | 10 (10.0) |
| Other | 4 (4.0) |
|
EP lab time (median [IQR], minutes) |
145.3 (130.9, 163.1) |
|
Fluoroscopy time (median [IQR], minutes) |
7.2 (4.4, 9.7) |
|
Fluoroscopy dose (median [IQR], mGy) |
17.5 (8.8, 42.0) |
Abbreviations: AAD, antiarrhythmic drug; CFAE, complex fractionated atrial electrogram; CHA2DS2‐VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, sex category; CI, confidence interval; CTI, cavotricuspid isthmus; EP, electrophysiology; IQR, interquartile range; MI, myocardial infarction; PAF, paroxysmal atrial fibrillation; PsAF, persistent atrial fibrillation; PVI, pulmonary vein isolation; SD, standard deviation; TIA, transient ischemic attack.